-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
WCagWIJ/E6xsNHlgGS8YmZAZ335aR+sOEmNWlHy7p9WikFXGn86FmspRSmfY5v4j
8q+M8CVK6qFLCUJ16VbC6w==
0001193125-10-047922.txt : 20100304
0001193125-10-047922.hdr.sgml : 20100304
20100304162545
ACCESSION NUMBER: 0001193125-10-047922
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 3
CONFORMED PERIOD OF REPORT: 20100304
ITEM INFORMATION: Results of Operations and Financial Condition
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20100304
DATE AS OF CHANGE: 20100304
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: COOPER COMPANIES INC
CENTRAL INDEX KEY: 0000711404
STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851]
IRS NUMBER: 942657368
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1031
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-08597
FILM NUMBER: 10657534
BUSINESS ADDRESS:
STREET 1: 6140 STONERIDGE MALL RD
STREET 2: STE 590
CITY: PLEASANTON
STATE: CA
ZIP: 94588
BUSINESS PHONE: 9254603600
MAIL ADDRESS:
STREET 1: 6140 STONERIDGE MALL ROAD
STREET 2: SUITE 590
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER COMPANY:
FORMER CONFORMED NAME: COOPERVISION INC
DATE OF NAME CHANGE: 19870701
8-K
1
d8k.htm
FORM 8-K
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): March 4, 2010
THE COOPER
COMPANIES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
1-8597 |
|
94-2657368 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
6140 Stoneridge Mall Road, Suite
590, Pleasanton, California 94588
(Address of principal executive offices)
(925) 460-3600
(Registrants telephone number, including area code)
Check the appropriate box below if
the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 2.02. Results of Operations and Financial Condition.
On March 4, 2010, The Cooper Companies, Inc. issued a press release reporting results for its fiscal first quarter ended January 31, 2010. A copy
of this release is attached and incorporated by reference.
Internet addresses in the release are for information purposes only and are not
intended to be hyperlinks to other The Cooper Companies, Inc. information.
ITEM 9.01. Financial Statements and Exhibits.
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press Release dated March 4, 2010, of The Cooper Companies, Inc. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
|
THE COOPER COMPANIES, INC. |
|
|
By |
|
/s/ Rodney E. Folden |
|
|
Rodney E. Folden |
|
|
Vice President and Corporate Controller |
|
|
(Principal Accounting Officer) |
Dated: March 4,
2010
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press Release dated March 4, 2010, of The Cooper Companies, Inc. |
EX-99.1
2
dex991.htm
PRESS RELEASE
Press Release
Exhibit 99.1
|
|
|
NEWS RELEASE CONTACTS: Albert G. White, III VP, Investor Relations and Treasurer Kim Duncan Director, Investor Relations ir@coopercompanies.com FOR IMMEDIATE RELEASE |
|
6140 Stoneridge Mall Road Suite 590 Pleasanton,
CA 94588 925-460-3663 www.coopercos.com |
THE COOPER COMPANIES ANNOUNCES
FIRST QUARTER 2010 RESULTS
PLEASANTON, Calif., Mar. 4, 2010 The Cooper Companies, Inc. (NYSE: COO) today announced
financial results for the fiscal first quarter ended January 31, 2010.
First quarter revenue increased 4% year-over-year
to $260.3 million.
First quarter GAAP operating income $37.0 million, up 13% from $32.8 million in last years first
quarter. Non-GAAP operating income $40.0 million, up 22% from $32.8 million in last years first quarter. Non-GAAP
operating income excludes charges of $2.3 million, for the 2009 CooperVision manufacturing restructuring plan, and $0.7 million, for acquisitions. See Reconciliation of Non-GAAP EPS to GAAP EPS shown below.
First quarter GAAP earnings per share (EPS) 44 cents, down 9 cents from last years first quarter. First quarter non-GAAP EPS 49 cents.
See Reconciliation of Non-GAAP EPS to GAAP EPS shown below.
First quarter free cash flow $43.2 million. Trailing
twelve month free cash flow $181.6 million.
Commenting on the results, Robert S. Weiss, Coopers president and chief executive officer
said, We are pleased with our performance in the first quarter. We enjoyed solid revenue growth, and our operational profits in both our vision and surgical businesses were strong. We also continued to generate significant free cash
flow.
Weiss continued, Within CooperVision, our products continue to gain tractionespecially with our silicone hydrogel
family of products, which were recently awarded Product of Choice status at Luxottica. Within CooperSurgical, we posted a very strong quarter and have now completed two acquisitions year to date.
First Quarter GAAP Operating Highlights
|
|
|
Revenue $260.3 million, 4% above first quarter 2009. |
|
|
|
Gross margin 58% compared with 57% in last years first quarter. The increase in gross margin was attributable to manufacturing efficiency gains
partially offset by costs related to the 2009 CooperVision manufacturing restructuring plan. |
|
|
|
Operating margin 14% compared with 13% in last years first quarter. The increase in operating margin was attributable to efficiency gains within
manufacturing and operations that were partially offset by costs related to the 2009 CooperVision manufacturing restructuring plan as well as acquisition related costs. |
|
|
|
Depreciation and amortization expense $22.9 million. |
|
|
|
Interest expense $10.2 million or 4% of sales vs. $11.5 million or 5% of sales in last years first quarter. Interest expense decreased as a
result of lower debt and lower interest rates. |
|
|
|
Total debt decreased $38.2 million to $743.3 million. At quarter end there was $378.8 million outstanding under the Companys $650.0 million
revolver. |
|
|
|
Cash provided by operations $56.1 million and capital expenditures $12.9 million resulted in free cash flow of $43.2 million. Trailing twelve month
cash provided by operations $254.4 million and capital expenditures $72.8 million resulted in free cash flow of $181.6 million. |
First Quarter CooperVision (CVI) GAAP Operating Highlights
|
|
|
Revenue $215.9 million, up 2% from last years first quarter. Revenue gains were seen throughout most product categories and geographic regions.
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions) 1Q10 |
|
% of CVI Revenue 1Q10 |
|
|
% chg y/y |
|
Toric |
|
$ |
63.5 |
|
29 |
% |
|
8 |
% |
Multifocal |
|
|
16.7 |
|
8 |
% |
|
5 |
% |
Single-use sphere |
|
|
46.9 |
|
22 |
% |
|
11 |
% |
Non single-use sphere, other |
|
|
88.8 |
|
41 |
% |
|
-6 |
% |
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
215.9 |
|
100 |
% |
|
2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In millions) 1Q10 |
|
% of CVI Revenue 1Q10 |
|
|
% chg y/y |
|
Americas |
|
$ |
86.0 |
|
40 |
% |
|
0 |
% |
EMEA |
|
|
84.7 |
|
39 |
% |
|
3 |
% |
Asia Pacific |
|
|
45.2 |
|
21 |
% |
|
6 |
% |
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
215.9 |
|
100 |
% |
|
2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
Selected revenue by material: |
|
|
|
|
|
|
|
|
|
|
|
|
(In millions) 1Q10 |
|
% of CVI Revenue 1Q10 |
|
|
% chg y/y |
|
Proclear |
|
$ |
61.9 |
|
29 |
% |
|
11 |
% |
Silicone hydrogel |
|
$ |
40.9 |
|
19 |
% |
|
151 |
% |
|
|
|
Gross margin 57% compared with 56% in the first quarter of 2009. The increase in gross margin was attributable to manufacturing efficiency gains
partially offset by costs related to the 2009 CooperVision manufacturing restructuring plan. |
|
|
|
Operating margin 15%, consistent with last years first quarter. |
First Quarter CooperSurgical (CSI) GAAP Operating Highlights
|
|
|
Revenue $44.4 million, up 11% from last years first quarter, with organic growth of 10%. |
|
|
|
Sales of products marketed directly to hospitals increased 15% year-over-year to $15.8 million and now represent 36% of CSIs total revenue vs.
34% in last years first quarter. |
|
|
|
Gross margin 61%, down from 62% in last years first quarter. Lower gross margin was primarily due to the currency impact of materials purchased
internationally. |
|
|
|
Operating margin 23%, consistent with last years first quarter. |
2010 Guidance
The Company amends its full-year 2010 guidance. Guidance is summarized as
follows:
|
|
|
|
|
|
|
FY10 Guidance Old |
|
FY10 Guidance New |
Revenue (In millions) |
|
|
|
|
CVI |
|
$925 - $975 |
|
$925 - $975 |
CSI* |
|
$175 - $185 |
|
$185 - $195 |
Total |
|
$1,100 - $1,160 |
|
$1,110 - $1,170 |
|
|
|
EPS |
|
|
|
|
GAAP |
|
$2.17 - $2.27 |
|
$2.17 - $2.27 |
Non-GAAP** |
|
$2.45 - $2.55 |
|
$2.45 - $2.55 |
Free Cash Flow (In millions) |
|
$120 - $140 |
|
$130 - $150 |
* |
Reflects the impact of CooperSurgical acquisitions. |
** |
Excludes the impact of the 2009 CVI manufacturing restructuring plan and CSI acquisition costs. See Reconciliation of Non-GAAP EPS to GAAP EPS shown below.
|
Reconciliation of Non-GAAP EPS to GAAP EPS
To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures, indicated in the table below, which exclude restructuring costs and costs related to acquisitions,
that we believe are helpful in understanding our results. We exclude restructuring costs and costs related to acquisitions
because we do not consider them reflective of our ongoing operating performance. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for
comparable GAAP measures and should be read only in conjunction with our consolidated financial statements and guidance prepared in accordance with GAAP. Our management uses supplemental non-GAAP financial measures internally to understand, manage
and evaluate our business and make operating decisions. These non-GAAP measures are among the factors management uses in planning for and forecasting future periods.
Non-GAAP operating income, net income and diluted EPS results and guidance exclude costs related to the 2009 CooperVision manufacturing restructuring plan announced in August 2009 and costs related to
CooperSurgical acquisitions. Non-GAAP net income and diluted EPS for the fiscal first quarter of 2010 excluded related costs of $2.0 million or 5 cents per share. We did not incur similar costs in the fiscal first quarter of 2009. The restructuring
costs, primarily severance and costs associated with assets, related to the pending closure of the Norfolk manufacturing plant and are primarily recorded in cost of sales. We expect to recognize total pre-tax restructuring charges under this plan of
approximately $24.0 million. We recognized $5.1 million in fiscal 2009 and $2.3 million in the fiscal first quarter of 2010 with the remaining $16.6 million spread over fiscal 2010. The acquisition costs, primarily legal and other due diligence
costs, are primarily recorded in selling, general and administrative expense. We believe it is useful for investors to understand the effects of these restructuring and acquisition costs on our total operating results.
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31, |
|
|
2010 GAAP |
|
Adjustments |
|
2010 Non-GAAP |
Operating income |
|
$ |
36,979 |
|
$ |
2,983 |
|
$ |
39,962 |
Income before income taxes |
|
$ |
24,426 |
|
$ |
2,983 |
|
$ |
27,409 |
Provision for income taxes |
|
$ |
4,003 |
|
$ |
975 |
|
$ |
4,978 |
Net income |
|
$ |
20,423 |
|
$ |
2,008 |
|
$ |
22,431 |
|
|
|
|
Diluted EPS |
|
$ |
0.44 |
|
$ |
0.05 |
|
$ |
0.49 |
|
|
|
|
Fiscal 2010 EPS Guidance |
|
|
2010 GAAP |
|
Adjustments |
|
2010 Non-GAAP |
Diluted EPS |
|
|
$2.17 - $2.27 |
|
|
$0.28 |
|
|
$2.45 - $2.55 |
Conference Call and Webcast
The Company will host a conference call today at 5:00 p.m. ET to discuss its first quarter 2010
financial results. The dial in number in the United States is +1-800-884-5695 and outside the United States is +1-617-786-2960. The passcode is 29168902. There will be a replay available approximately two hours after the call ends until Thursday,
March 11, 2010. The replay number in the United States is +1-888-286-8010 and outside the United States is +1-617-801-6888. The replay passcode is 87281284. This call will be broadcast live on our website at www.coopercos.com and at
www.streetevents.com. A transcript will be available on our website within 24 hours after the conference call.
About The Cooper Companies
The Cooper Companies, Inc. (www.coopercos.com) manufactures and markets specialty healthcare products through its CooperVision and CooperSurgical units. Corporate offices are in Pleasanton, CA.
CooperVision, Inc. (www.coopervision.com) develops, manufactures and markets a broad range of contact lenses for the worldwide vision
correction market. Dedicated to enhancing the contact lens experience for practitioners and patients, CooperVision specializes in lenses for astigmatism and presbyopia. CooperVision manufactures a full array of monthly, two-week, and daily
disposable contact lenses featuring advanced materials and optics. Headquartered in Pleasanton, CA, it manufactures in: Juana Diaz, Puerto Rico; Norfolk, VA; Rochester, NY; Adelaide, Australia; and Hamble and Hampshire, UK.
CooperSurgical, Inc. (www.coopersurgical.com) develops, manufactures and markets medical devices, diagnostic products and surgical instruments and
accessories used primarily by gynecologists and obstetricians. Its major manufacturing and distribution facilities are in Trumbull, CT, Pasadena, CA, and Stafford, TX.
Forward-Looking Statements
This news release contains forward-looking
statements as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of
historical fact, including all statements regarding anticipated growth in our revenue, CooperVisions manufacturing restructuring plan and expected results of operations and integration of any acquisition are forward-looking. To identify these
statements look for words like believes, expects, may, will, should, could, seeks, intends, plans, estimates or
anticipates and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.
Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are:
adverse changes in global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing uncertainty and instability of U.S. and international credit markets that may
adversely affect the Companys or its customers ability to meet future liquidity needs; limitations on sales following new product introductions due to poor market acceptance; new competitors, product innovations or technologies; the
Companys failure to realize anticipated savings, or its incurrence of unexpected costs, from CooperVisions manufacturing restructuring plan; a major disruption in the operations of our manufacturing, research and development or
distribution facilities due to technological problems, natural disasters, CooperVisions manufacturing restructuring plan or other causes; disruptions in supplies of raw materials, particularly components used to manufacture our silicone
hydrogel and other hydrogel lenses; the impact of acquisitions or divestitures on revenues, earnings or margins; losses arising for pending or future litigation, including the risk of an adverse decision or settlement related to claims involving our
securities class action and derivative litigation, or product recalls; interest rate and foreign currency
exchange rate fluctuations; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill; changes in U.S. and
foreign government regulation of the retail optical industry and of the healthcare industry generally; changes in tax laws or their interpretation and changes in effective tax rates; dilution to earnings per share from acquisitions or issuing stock
and other events described in our Securities and Exchange Commission filings, including the Business and Risk Factors sections in the Companys Annual Report on Form 10-K for the fiscal year ended October 31, 2009,
as such Risk Factors may be updated in quarterly filings.
We caution investors that forward-looking statements reflect our analysis only on
their stated date. We disclaim any intent to update them except as required by law.
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Balance Sheets
(In thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
January 31, 2010 |
|
October 31, 2009 |
ASSETS |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
1,822 |
|
$ |
3,932 |
Trade receivables, net |
|
|
174,945 |
|
|
170,941 |
Inventories |
|
|
251,842 |
|
|
260,846 |
Deferred tax assets |
|
|
25,339 |
|
|
23,360 |
Other current assets |
|
|
42,460 |
|
|
44,799 |
|
|
|
|
|
|
|
Total current assets |
|
|
496,408 |
|
|
503,878 |
|
|
|
|
|
|
|
Property, plant and equipment, net |
|
|
586,716 |
|
|
602,568 |
Goodwill |
|
|
1,254,767 |
|
|
1,257,029 |
Other intangibles, net |
|
|
114,963 |
|
|
114,700 |
Deferred tax assets |
|
|
25,027 |
|
|
27,781 |
Other assets |
|
|
43,519 |
|
|
45,951 |
|
|
|
|
|
|
|
|
|
$ |
2,521,400 |
|
$ |
2,551,907 |
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Short-term debt |
|
$ |
19,140 |
|
$ |
9,844 |
Other current liabilities |
|
|
159,667 |
|
|
165,570 |
|
|
|
|
|
|
|
Total current liabilities |
|
|
178,807 |
|
|
175,414 |
|
|
|
|
|
|
|
Long-term debt |
|
|
724,178 |
|
|
771,630 |
Other liabilities |
|
|
51,313 |
|
|
48,065 |
Deferred tax liabilities |
|
|
15,046 |
|
|
16,456 |
|
|
|
|
|
|
|
Total liabilities |
|
|
969,344 |
|
|
1,011,565 |
|
|
|
|
|
|
|
Stockholders equity |
|
|
1,552,056 |
|
|
1,540,342 |
|
|
|
|
|
|
|
|
|
$ |
2,521,400 |
|
$ |
2,551,907 |
|
|
|
|
|
|
|
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Statements of Income
(In thousands, except earnings per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
Three Months Ended January 31, |
|
|
2010 |
|
|
2009 |
Net sales |
|
$ |
260,258 |
|
|
$ |
251,142 |
Cost of sales |
|
|
110,495 |
|
|
|
109,007 |
|
|
|
|
|
|
|
|
Gross profit |
|
|
149,763 |
|
|
|
142,135 |
Selling, general and administrative expense |
|
|
100,578 |
|
|
|
94,992 |
Research and development expense |
|
|
7,626 |
|
|
|
7,232 |
Restructuring costs |
|
|
363 |
|
|
|
2,954 |
Amortization of intangibles |
|
|
4,217 |
|
|
|
4,177 |
|
|
|
|
|
|
|
|
Operating income |
|
|
36,979 |
|
|
|
32,780 |
Interest expense |
|
|
10,225 |
|
|
|
11,457 |
Other (expense) income, net |
|
|
(2,328 |
) |
|
|
8,145 |
|
|
|
|
|
|
|
|
Income before income taxes |
|
|
24,426 |
|
|
|
29,468 |
Provision for income taxes |
|
|
4,003 |
|
|
|
5,595 |
|
|
|
|
|
|
|
|
Net income |
|
$ |
20,423 |
|
|
$ |
23,873 |
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share |
|
$ |
0.44 |
|
|
$ |
0.53 |
|
|
|
|
|
|
|
|
|
|
|
Number of shares used to compute earnings per share |
|
|
46,123 |
|
|
|
45,141 |
|
|
|
|
|
|
|
|
Soft Contact Lens Revenue Update
Worldwide Market vs. CooperVision (Constant Currency)
The data below is extracted from a
compilation of industry participants revenue by the Contact Lens Institute (CLI), an independent market research firm. This data is compiled using gross product sales at foreign exchange rates set by CLI. It therefore excludes items such
as discounts, rebates, currency hedges and freight reimbursements.
Worldwide Manufacturers Soft Contact Lens Revenue
(U.S. dollars in millions; constant currency; unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Calendar 4Q09 |
|
|
Calendar 2009 |
|
|
Fiscal 1Q10 |
|
|
|
Market |
|
Market Change |
|
|
CVI Change |
|
|
Market |
|
Market Change |
|
|
CVI Change |
|
|
CVI Change |
|
Sales by Category |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spheres |
|
$ |
1,131 |
|
2 |
% |
|
4 |
% |
|
$ |
4,652 |
|
2 |
% |
|
7 |
% |
|
8 |
% |
Torics |
|
|
255 |
|
9 |
% |
|
6 |
% |
|
|
1,049 |
|
7 |
% |
|
(2 |
%) |
|
9 |
% |
Multifocal |
|
|
66 |
|
24 |
% |
|
7 |
% |
|
|
253 |
|
21 |
% |
|
17 |
% |
|
8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WW Soft Contact Lenses |
|
$ |
1,452 |
|
4 |
% |
|
5 |
% |
|
$ |
5,954 |
|
3 |
% |
|
5 |
% |
|
8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales by Modality |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Single Use |
|
$ |
509 |
|
2 |
% |
|
8 |
% |
|
$ |
2,011 |
|
1 |
% |
|
14 |
% |
|
10 |
% |
Other |
|
|
943 |
|
6 |
% |
|
4 |
% |
|
|
3,943 |
|
4 |
% |
|
3 |
% |
|
7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WW Soft Contact Lenses |
|
$ |
1,452 |
|
4 |
% |
|
5 |
% |
|
$ |
5,954 |
|
3 |
% |
|
5 |
% |
|
8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales by Material |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hydrogel |
|
$ |
931 |
|
(3 |
%) |
|
(6 |
%) |
|
$ |
3,846 |
|
(4 |
%) |
|
(3 |
%) |
|
(5 |
%) |
Silicone Hydrogel |
|
|
521 |
|
20 |
% |
|
126 |
% |
|
|
2,108 |
|
20 |
% |
|
112 |
% |
|
153 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WW Soft Contact Lenses |
|
$ |
1,452 |
|
4 |
% |
|
5 |
% |
|
$ |
5,954 |
|
3 |
% |
|
5 |
% |
|
8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales by Geography |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Americas |
|
$ |
524 |
|
6 |
% |
|
4 |
% |
|
$ |
2,294 |
|
5 |
% |
|
4 |
% |
|
11 |
% |
EMEA |
|
|
435 |
|
6 |
% |
|
9 |
% |
|
|
1,755 |
|
6 |
% |
|
7 |
% |
|
8 |
% |
Asia Pacific |
|
|
493 |
|
1 |
% |
|
(2 |
%) |
|
|
1,905 |
|
(1 |
%) |
|
3 |
% |
|
1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WW Soft Contact Lenses |
|
$ |
1,452 |
|
4 |
% |
|
5 |
% |
|
$ |
5,954 |
|
3 |
% |
|
5 |
% |
|
8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States |
|
$ |
451 |
|
5 |
% |
|
3 |
% |
|
$ |
2,014 |
|
4 |
% |
|
4 |
% |
|
10 |
% |
International |
|
|
1,001 |
|
4 |
% |
|
6 |
% |
|
|
3,940 |
|
3 |
% |
|
5 |
% |
|
6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WW Soft Contact Lenses |
|
$ |
1,452 |
|
4 |
% |
|
5 |
% |
|
$ |
5,954 |
|
3 |
% |
|
5 |
% |
|
8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
COO-E
# # #
GRAPHIC
3
g30272g13t10.jpg
GRAPHIC
begin 644 g30272g13t10.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`5`+&`P$1``(1`0,1`?_$`)(``0`!!`(#`0``````
M```````*!P@)"P$&`@0%`P$!`````````````````````!````8"`0,"`P4"
M!PT"#P$``0(#!`4&``<($1()(1,Q%`I!42(5%F$7\'&A,B-5&(&1L>'Q0C/3
M))34EQG!T8*R<[,T)34F-K8G5W)#F^T-I'R>[-BSB%$U0QE4?F8QA*O2&^?M$
M@U[B`\9UY,R9C(B8H',J7J(`'J$6/C-Q2\Z_D?T;*2F'LY(:[JL
ME8D(5WTYJN,ZW:INF;FO--4B7L"_IH(FDZY8;`57V)=M((&$6:@II=OM#T`>[`L(
MY?\`E/\`(/Y0?(!*\%O'=>'FJ=:QMNF*C#3,$*<7)V-I5S$2LVQ+?9%$7PQ]
M8;G73]MN5`_;UZ`81'K@4OY0D\VO@TL6L-Q6_E.^W3K"U3S=@Y"1<)V*FOID
M#(J.ZE:(8[&,58#(I*"#1P"I@.8@B``("&!)9V'YM->5SQ"1GDH@:^FZL=J@
MF-8K>NG"HBFGNM^FHS/5'2P=IQ91K]`ZBA^GJF4`'IUP(U_%/67G)\U<;?N2
ML1R\E=1ZXCK-)0E:%%XA7*O(V"+$ZB]?J%?2CI([>+BS'(FJZ%8Q2F4`>T>O
M3`KGXY?+/SIX.\_FGCO\BEO=[#K,I>D=:.+'93HO9RDV*4!3]+V2(LZ*;8DQ
M29CV5/06Y`'T$!ZA@3O"&`Y2G*("4Y0,4>G3J40ZA_(.!Y8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8%G_`#7W-R4T7IY2[<6N-*/*?8J,NBW6UNO?D==`6$^6
M<+O)8DXM"3Q%%&QDBD*C[`"<3_$.F!@-UW]05S#LO'6Y\NKGXQRTWCC3[RPU
MDO?`Y`-)%RO>B;OAM%V>(-#C1&YT6U>M$@N!G`J"506PAT`#=0"474[7#6V(
M9R45)1+U19DSG7H&!]M&1CW*Q
MV[=^S<.$^ON((ND%5D^@]![TB',KA%2(E`PMD)650KXQHKB`=I5%RMS@3K\>P>F!FS
M\&-NIDQXH>(S^OR,:6.KVKD(JP*)KHD2C)B)7<#+HR1NXH-W+;N`5.\0$`'U
MP*PUCR%\(.2\O>M$<=^1^K-B;K>4N_DCZ?4Y'YN>%6&B'*,HJ0I6J8"5BJN0
M#CW?$0^.!">^FNG(37WE[O=8V&Z;PMNEZ7N2L11)DQ6SD]G1F(A=W%)BN("$
M@[0(/:3KW'Z=`P,^WU8%SI\5XY*]3I-['A<;7O2AN*I&G52&262B"29Y9XV2
MZBL5JT*\1]P_3M_&&!'!V!0=B-OIF]$61=M)?I=+FS8[*N0Z:GLH5^;?%+"R
M2G7T*Q5,T5[#_P`WTP)5'TQ-MJ$YXJM;PL`_CCS-2O>P(FWQR"R7SK&;+(ME
M%EGZ`&]TGS29@,4Y@`#@`]!'I@1>?-1)1NVO/9%UW4ZR^
M=[@UXP64A6-D7$=C;]-'BXA=$Z_5;2EH367:BZBU[F[!46]-A)$I1*1RL58_
M<'0$AZA@0B.2?U?_`)*MQ2CV/T%6=9:`JCE1P+=E&UYQ>KHBF=4WRA"VAZJQ
M3(**)@*;L9%$Y_7KT],"Q)MYX?.FA+*W4.3._EXX_186+BK.E:>FF4>WJFU_
M)2H%2$P]!'W>G7[<#(MQ<^L-\ANGIEA&\H->:[Y`4UN"""R",*XUI>P3]XOS
M3D]B1&6:2#@J`F$A%69.I^@"?M^`3Q?'IY--`>4OC!:-ZZ#0M44S@BR=4NM;
MMT82-E:U;"01WKF.351<.$))B":@&1=$[`5)T$2%'T`(Q#:+:V#Z7[D;77K]
M6-C[-SVVC6GTDB80<,&%@\AS*(>NFQ_44W*+9X<4S@'X#]#?9@>/+'2$IX:>
M0CZF^,:;V/67>_?&KL&X7J#D)Z5OR$I=*ET0ZMP2XC\U82V<">1&A=K<4*5:+E8J99]A[@4YPNMD7GF!4;-74
MI6_U"S:U=4&+3E+.5H[>27R9'!31[Q($C"(D`1">K@,!@,!@,!@,!@,!@,!@
M,!@8:_,>^\<>TM$N.*//#?E-T>XV6W/9-:STV_.RL%?LE=[_`,OML$)$3F4_
M*7#G^E3[B@H0PAU#T$`A80.BMEZ0A;GHOC'YO]$L^.UT?.RSD7`;(>5YM(1[
M\_19S*5AO%2BK%P[2``7`JP`<2_$,#+YX>Z1X=/%W9[#N_9?D:TKMSDI9H-W
M7595C(.F%;HL%)"0\Q%0[,4W8O7TH9(@.'0B0QP)T[/7T"U3R-<:_&+O#D-+
M?2)N@K(^PJ4YB@/[
M,"UAGQGH_+K9M2M'DP\XFD+E3*B9LV%I';%4N=H=0;4Z1E(>".FRC209I)-(
MI%'/8J8I0^`X$I2Y\LO`9=^&*W`J1Y0Z*:\>DZ&WH,97VMB4(^AF3)`48Z:8
M/_R_O)/M'`BN#GM`QE!,(^@],"+,PXT.>)%INJWCR\Y&FJWJ>ZK*M9!\-Z=4
MATI'./<*1K92&82[1:2:H*F3!?O3,IZCTP,B7B-XM>,#CMR9IW(;D=Y)]*\G
MN5\S:#DUM68.=6?Q3'8$^8`2GW$@HFK^IK6J!#@@H8B'LB(B`#UZ8$ZHI@,`
M"7U`0`0$/@("'4!#]@A@>6`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!P/\``/O]!^S[<",)
M]1IYR_\`IEZJC]$\?WD>_P"7VYH-Z>)D%/;=H::I:Q!;K7J0:]3%5L+TY_:B
M6ZG9T.877J5("F"#KXK_``Y\QO-KNNR;6M=HL$)I_P#5:LINCDM?C/IN0GYI
M^]%Y+P]4*\5(>U6YT94QE`]Y)!H4_>8P]OMB&PRT!XG/#KXF-=M+=,4?4M??
MPX%6D]Z!_I%@*90JR<*+,[0A_Q&.4!+T#N#K@=AVMX^?#W
MY9-:OK*77FA]O1]@:*MX[<&F74#'W2&.Y;B(.X2S5\@KL'()*`8ONHG((AU[
M1$/0/G^&7Q4R/BFU;R'T.K?6.S==WO<3J\:XECL1832%/D81-D,#:&W>HFM)
MQIP%$RY#]K@`$X%(`@0`O_1X2<3&VD)3C:CH37B6AYFY.=ARVK0B!_23ZZN[
MHEL9U97#`5Q$TFM>$"29C]W3YHH&Z?9@6Q-U%W/3:
M%-ZWJ4S,H-F-W3M/BXU`[QR,5+F'^G0%$>H=>O0.N!BXXFWWZ76"Y
M.QNX.--OXA5?D4M/*RM+DDYJ1A',38YE!TQD75'8S"Z4+%R$H206*N5$H"/O
M&[2@7X!)_82+"49H2$8]:23!TF19L]CW*+QHX24*!B*H.6YU$5DSE,`@8HB`
M@/7`]S[_`.`X'JNWK./:N'K]TW8LFJ1EW+QXNDU:MT4RB=19=PLK43E?3*_;+`HU;PE8V/WTB8DWKOM!*
M/:IR1C-3O@$W04Q5`?0>G7I@9D&KMJ^;(O&3EN\:.$R+-W359-PW<)'`#$40
M61.=-5,Y1]#%$0'`_?KZ=?X?WOO#`I'N??FEN.M,?;#WKM"E:HI,:03O;)>)
MYC!1B)2D.]#=ON,);YIH#E/[>OMAZ8%_'%#S!>.3FK)-*YQ_Y2:XLEV>-TW1-?RL
MJG7KJ1%0I!*)H24%$RI@.?L$J1U#`"TJZJ^^.2530OK$4_G=<
M4M0ERO3--01*59W"1:W1JF!BB`@HJ4W4!]/0<#&PQ^KO\.KZ6;Q0VW?[(KAV
M#3\U?:5OV8$&3ZOU,@[XXD*'`!ZTB\%*(
MF$.G^TQ_KZ8&/7Z:N,B9OG_>Z].Q4;-P3CC!N:5<0DTS0DHY63B8J+6CWXH.
M2G(#IF83`0X>I0./3U'K@8IN/57F-I1#B*8M]@1XRM&F9E
M>3DR1L-=FI3MTA@GI$S%.`F+Z$#IUP+P]H>,KDQMG?',&S5[74(Q@-.;RL-&
MV$GI6`)*T#7TXU:IK."LHDCU!>%I#8B7]$L7W0ZF'TP/#>7C5K-?T!XR+%H2
M6L-ZY!\\U)Z%D:5).%"17ZF8O(YLS2@4SE-^4LFA5U#+^A^H=/ATP.F7[Q%\
MGJ9*$KD$%6O-K:\BV'%B;JT;)MVDQ'[8E14%H,:S[EEYBH&*W5$9("IE*"8_
M@]<#(#&%>.OAT\L^F;A-URX;!TORAU-29UY'-$5AJ=B0"T'G(N%D1ZKJ1Z
MQS)@58HD!;L'\(=,##WP413/S5XB$]LH==_4(>@@(AT!5UT,`]?B7`W&C;_0
M(_\`D4O_`#9?A^S`_?`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`Z+M"_P`'JC6]]V=9EDV]
M>U[3K)=)E554J)0CJU$.YAT4%3]2D.HDT$I?0?Q"`=!'`T[!0WIYYO+PF@X?
MR4G-\D-PKMD'S@IT4J%I2OK.EV**@]%D6"-5UW%%1)U#M.Y*4.G4^!LG>97*
M#B;]/9XUJS&TBKQ<4RI\`EK+C_K5@FFB_P!D[/5C%GB\I-KIA[KE9VY3<3,R
M\/ZG_&`"7O+VAK.+5L/R>^=_E8NU3'8G(;:,XZ>R,;3:Z#QKKW5M6=/4RK`R
MC2*FB*A3H8'!>Y10QC%(`^IQ$0$,MJ7T;GE!/3@EE+;QS0N!FHK?I(^PI$S8
MKCN#M9GL"=:.U`XE^)P3$@#Z=1^.!B0DFGE!\#W*B,1?.MA<&O6[D%BUZVE0.=M+1G>!53U^TM$?G&O4!]@#BB8QC)]PA@-^
MI;^H0N?%N=EN!?":U(0NXG$,E^_+<<4L"TIK5K,-4G3*F4U9,?:96UXP<)K.
MGW<DGK23D+1(LW)A%8J*?9U,'0_P`>@7FG1.N=YL*\P
MB+56IY@L59A*P$['H2D5)-U@'M%!TPU\#N(%[F(;CKK^;/1]@RM(&LUO'8[=>ZH4?4I<#IO//Z5GR&<,J'/;AU
MXM6N2FNZ97^$AXT5W"L]^BURN'#J*:Q#<[ETH@Z.=L!1+VF]!
M$+G?IO?/UM/C;N2@\(.65\?6[C1LB;:5#7=IN#MT]FM)6^0*5E`Q;23<**+*
MTJ>EBI-3M%0_V5TZ%8I^WJ3`V"'/_FYJGQ[<4]I\I=M.C'@Z%!B>"@&AB'E+
ME;Y-5..J]8BD143%523EW20+'*(^PU!180$"=!#4H[XY,>1CSR\R8F$4"W;8
MOMSFWL=JS3-4.\2HFLJJLL*IVS"/(<&$5#Q$>D+B2DEP[U3%55'H)@3P)%6E
M?HE]PV*B1\MO?F)4M:W]TD0[ZH4F@+W^'BE3(%,=`;,XL=6DZDX2D)7:NK$Y*)LU"!H\2,SGK55TU7
M#^"BDW1T`3>I.ERE7.`"!>G=@26OI?\`SQ7CE8N7@/S#N@6;=-?@EWNB-D2_
M0L[L6L037YB4I]D>"8WYO:8!@15R@Z-V'58(]@@8R7<(5@^J(\VERX-46"X=
M<7;0:O\`(?<=<7E[S?(HR9I/5FNG"RK--&(<%5$T=IR
M]0B1>++Z>_FQY9F3[>LK/IZ=T5*3#]-3=.R6TG,S=XFCN559)W3ZZJLS>6IH
MD]]TKMZ+I)(CC\("<3>@9_YKZ(BMI418EG=^7_F/]-V_'V_3`BU_5$\.-QIOYO;U#X]<#%?XR.$/DLX37&T\Q--:)
MTCO.O+4"[ZYX#"&!T
M?6?'?>VC(*D[$I&B.+\[!:
M*?R;CMPLUJJ[EGKUDXF(:2B5*Z@/S8F2(F2;NR5?C6+2LOTG`^X`**'_$'3`K)R
M*T?Y#&^F.66K]KZ%XZZA@_(CM*/WM/6^Q[Y29J*W2#(HHH:G$)4U"NH!'\T`
MP)>GME5#H80-@6,<)/%UR9C.8'%V9)9N/,XG`;HJ$R\BZ]N!.1G'K*..Z.Z)
M%QPUU$7KH""`@GWE[OOP-HV@42))$,'XBID`WW=Q2%*(?R8'ZX#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8CZCC@`$DW[/O_C'
M^_U]/C@8(/J(^`5(YQ^.#=#M:JLI#+E*B1Z51$QNSW2D.'02^H05OI7>65NXV\^+[7HQ95>I;.XZ;C5LL6HH8[,'
MNLJ5,[0@9,C,QRIG>D?U0K<#A^+V5SE^`X&,7BKKRP^4?RHZXI]WDG4A)\Y@$ZANIC"(B
M(X'?AZ"`@("("7U`0Z@(#\0$/OP-99]8EP8H.A.5FG^4.K*C&U.(Y(UR6;;-
M1BBHLH]YM&N.`(E+MXMNBFBW7FJXD"CLY?\`2.4Q./J;`S"^&[R'6%I]-KR'
MN,Q(2!ZVUL[4I#=WHFW+Z!TP(QGT
MQW&JMTN\3JJ/LV[IJ-L@@^2GK0T]Q*$DY%)P4X2+AE:95%_T/
M_.62`P]>GJ&W``.TH```4H%``*`=H%``]`]/0`#`_-9%%RDJ@X227072.BL@
ML4JJ*R*I1(HFJDV8_I]F!>=]1GSSO6_N#GB"
MUDXFRN(J\<@04*7'-758F#HLUI0GS
M:IR*%%100`?0`P,]/_\`N#JO7K_8!L'P_P#O?'=?[_Z$^&!\&U?6LZQO59L-
M+N/CJEI^I6V$E*U9H-]NR-49S$#-L5XV6C71!H@=4'K%R=,P!T'H;T'KZX$1
MG@+O%?6GE#XV[BT]%+T"->\M:>%6K#.1,LI6J1L+8S>`/40DO:(+M-C4K"=@
M902![I2B(@'7`O8\PMN)S1\\FWJ^^E':\!<.3FN="L#+JF1_*J_&S-8UDHU;
M=>\&Y4/95/W`'JH83=/7`VWFF]5U72&J==:AI$:RB:KK:EUNEPK-BW2:H`RK
MD0SB4ES)(D(4SAR1I[BAQ_$O[<#G`CB_4%M8^0A.+,4
M\3%1Q+7FQ1S'_P![#58H.'*4*4.IPCI#YKN$.G3\/;_=P+?/&IL$T!QI\A?%
MJ>.JVD];U.T6M&$6O9YOV"2,4Y+._*NS1#(T60ICMQ$P$4^_[/4*':_
M?#!?[%"P/SEITON2[[!@U27E5P]/&Q3Y%>>CT;(6&`R*#E,I#G0^7-_H@#K@
M=BW9S,C[]X<-$ZZ+)"\L]AV"SU%*-$[^="3>1M)>)LEB.K`$.HL]*Y&42`R8
MMB]P)AZ^F!9USMW%5O'SOSQ(:"W/!2TCQUD257GY
MD.UD6X*4EPV`Z*1R)D$51ZAT^(9LN3V_?%IY9>-5ITQJ+D%JB2W5/5@5M--X
MJP)TS9E=M[(S=Y#M8GH5LJDN=5`$%&H&.0Y3"4>@?B`+./,'#N:3IWQ^UF^1
M*[&QU_7#F#E(QQ=#55=B_:)UR.=IK"2-E`?*E,'41ZEZ"'Q'K@7X<-/$/I:B
M670?)>*W)L*0LL.E7[\UK*]F;R$(O(/&'S`L#`42'<-4P<]O\T!'I\`P,^H?
MQB/V?WOO_;ZX'.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!@%^IPU\[O?ALY5NV+=5RYHS&
ME7(2)+"D)&K"]UMF^6%,$U!<@DU?&'L#I]_7TP(]WT1-YK:
M.:/0F^I9YHW23;.8J8UFH:I*-'C0JJITU54(PBI3FZ>\0X'`.@X&9GK^S[.H
M?X.G[!#`QR^6_D!5>,WC@Y>[2MKZ/:LT-+V^IQ[=\L1,TG-7Y@>DQD>S3.8#
M.GAW4^!BD*`CT((_`!'`U@7TZFD+'N[R)-8ROQLH]_3N@.2$F]3LTV;%((E`RBI?7`HEX9]B1/%+S`<1;)M4XP#37^_G5&M
M0.>A!C9J79V'716S@3]H)`A8I5--03"`%`!$>G3`W0A3%.`'*(&*8I3%.7H)
M3%,'4!*8!$#%$/NP/+`UZOUM>[:N_NG#OCXQ50>6F#AK7M"=%NNDJ>(8R"RU
M>CY$IA40+K5-BH_TL7D/V!+MU48G<,E:YVMBH
M42BNQJLS`TYZJF`@`^V,C&*``^H#T],#&!])EO\`UYI7RHP-8OBK5BXWEKNR
MZTITN^7(V9L+23VK0U1574$I"JRK:"5:H@/\Y54I?B(8&U_Z_'T^'_
4FF24?-,N/FN('6TI+Q9DUVRUA?=+/-1XND
ME#D<.(5[*&:J].GMJ)F)Z]N!2WS=Z!O^J>('A?L5HBG;=A+\-9EDNY%L9-HQ
MDIN^2%WAHTZPC^)V]J\XBZ`H@`@7K]V!(Y\$/B#\1GD+\<>G]T7_`$1%V7G4?7K@>^M]-3X<55"G_LF027
M:LJOV(S$D1,WND.3V3%[QZHI]W<0OV"`#U],#L-0^G4\1M$M-(N=8XLPL;9=
M?V>$M]>E4Y>1,L2=KLTVGHEP][CB5T5K(,T^A1``$A>W`UL.]%3K>>2;.H/4
M?^I)`%]`Z="DY`1A"AT_84`P-R]@,!@1Z/.\N=)SPZ*2,=R`FVNY[CM*Z2>%
M`GS-?`YE.Y\S^3)T'KW_`(OXO3`M/Y,N`XI>1S;;G\HDVE"Y)<>I=`\@SJ*;
MU@M*VV(:HNT%Y;\R:E*=FXBP`4_:'M[P]?7`O^\&$2A.<';5"RT2NW8RNT-D
M1KIA(0"<&*S1VHBB<18?-/B*)JI*^AQ-Z_'I@8:M'<<8X_E+:\8))I)+Z^UQ
MNRQSR!35DB40XC8-1-\1)O.#(J%,[B/*Q98[
M3?W!S65BY#.UZ?L&AZV!.?G;1K*PNVMMJ+)BJ59.S!"E9M5P9QZA"
MBJJ5003[@Z@/7`RM[KW]L/D#XV_%KMK9*<[;K[+4FY5R>L9ZR2S/YQ6`)ILK_8>./(!NNS.DHK4W4ZK%QEC(
MBH<@!%MK`RCY0%>HA\D!CAU^T)M_U*WBH=^3CB%4=\\=&$;;]^Z"C%[A0RQ!
MTW;G:&J9UJ61FZC!O$C&17.X(JE+,N@B"ZC<$RB'N=<"#)X>?-7R+\->U;;6
M%ZL^O^CK9-"EMG0UA>.:^\CK'&JECE['673ALZ&NVU@DW%!8JC=1)P0GMG*4
M?Q@$U%C]8]XLE:6C,/Z[R.9W0[83+TY'6K!TV1>`B)@1+8OU.BS5;BMT+[GM
ME-T'KV?9@0[/,_YX-^>8"U5O552J4AJ[CC7+$DZI>HHE^M-V"ZVH_O1<=8K<
M\9MFGYI(*HNA*S8$1%-J98P`*AA[L"8_]+3X@[=P*T#:N2_(>G+U7DGR*8-V
M3.LRJ8)SFO=1(.F\A&0,HAU.#>6LK]DC(KD_"=(G8D/7H(B$83ZF;PXWOA1R
MBM','1U1G'?>MGOD&"Q^\Z":28J@3M`X=<"%1K^B\X_/KY$3NGY
MI;8.UMP6EB[OEP(T51IVI]XW:=80[AZ=<#4F:S;[1CYTNP]4-;2G8=4+Q5_P#U-4VSM:0I2D/+L1BK
M,HX9D4.P28S!D.U8P=A5!#KZ8$[7@W]9U$PFN(*E*)*J'$P%)_-`.L>0+ZRQ]<-H9NB6JRQ:[%;=6S%VBDE4TWB1VKH:S3VB:J/YTD@J)VSY5YT;+`0Y4C"7H(
M8#O"OXK-Z^7/F9&VZ[QUDDM"5J]_O"Y*;DL!5UVLVZ4DOU"]JJ,B[`"SMMO<
MBKV+)%.!DVRRRYA#L`I@V&_G5\3\+Y#O'JMIG5-?81VV>/3)E;>-L$)"*T-("IGZM9VI(G9-4C"!"N@0$1#IUP->OX=_+YR`\)'(N]TB]TJQ3>
MG;-8AKN_=#S@N(2;@;1`.C0ZUK@D71!)&W.N@@=!0IR&3>-R"B(EZE.4-@;K
MGZFOPZ["JT595N3K6A+2;<5UJWL&OOH"R1:I$Q.HVD6"1GZ2:O<`E*)53E./
M3H/0<"D'(#ZK?Q*Z;@W+BH;*N.\K(HT54B(/6E25>,7#LI0,FWE9V1>,FT0B
M?X"H*:H@/P*.!T[P7^F7CP$`;)M4TD3'_``F-TZB$"G>H(AYY9P&ZBBB?_4E@/QJI
M^V;O'D!&"H7LZC^$BG4`'KZ@'7`W+WW?M_RX#`8&RW\9-[N$VV.1T)I
M"XZ)UY7+U?:69Q7K(R>2B$:N$"];L@!4C\QC$63CUD5``O3U[OC@7%>)#1&V
MN.7&20I&[:7&Z]MKC8UKFDX5C*(R""D7(&9F9/!7(!``ZX)F].GITP+*]5<.
M.3$!Y<+MR)F-20C'2LG;[E),-AI3*"SYRPD4601ZXL2AWD,Y%(P"'7\/;@59
MY8<8N>)/(I2N;O$>5UV]JU#U$E0;KJBYV$D6ANI@^>.',C`HO2-G1:Y*1`-T
MC,WRA%`*HIT`OK@=WY1SW+_FIQ_NG%RG<:9K1LAN6NGI&R]G[3EF/Z6U_69@
M2H65]4T46PGO4N#3J1HF'RH")N\>G;@66\]O&1M**T1PIX[<1-71FS*+QRIL
MK5'CB9F4M%;_U0=.17$2G]YU*NFIUCC]A@`.OI@?KQ!USYDJIOK2,?MUS:
M8_0<%8(UG[%?R+<4J626V33X1-OR/H==
M8B,]=ZQ%(M6<9L>*;-^Y22FJK&MB(O4"$`ZC`@K=QC)"4P8__I_/J86W&6NU
M+A1Y`I>1=:;A5`@=4[W^JPWK45>KDW&8CM_\=YZ%;#;UEVY$6KVW-F*+J.M
M*""(`)2G!NM\!$_PP,&KCZ("LC8T5FG/:9)4_=.HX9K:6:GG`2%;N300=$O!
M6G^@_"8YB=>[UZ?9@9W?'?\`3>^.GQ_3L3LEA27V]-UQ)VKN-V+MT64XC691
MH<3)2E)K/RH,*X^$IA*943N5!`1`#!Z8&?X``OH`="@``4`]```#H``'0```
MP.D[%UM0=NTJQZXV?48"^4*W1J\/9JE9XUO+08]NV%7$7)#/*U0]?-:*Y>M"J`
M8Z1+`_L5B5:+*)?A[@;'`!'K@2TN$WCSXC>/37:FMN*FH8'7<;(`S4L]@*F1
M_<[L_8M_E6\I;[*LF5[,2!6_0G=T(GT#T(`]1P+:_.M__)7G!_\`B!;_`.8(
M/`@9?2`P4+:O(KM.JV:(C;!6K+QLN$+/P4RQ;247+Q4A,PK9XQ?,W::J*R"Z
M"ABB`A\!P)+O-3Z6'Q([#MRMHJUUDN(EBM+P/9JM?N$&G1U'#MP1-LC7*3."
MW';'(L1O,G9)RCJ1C5U"=%4BG1]Q,1*(]!'`E/Z$X\:0XNZVA=0-8U'4FM
M:][XQ-1IL4C%1;=5RL9=TY.1/JJY=NESB=154QU#F'J(X%9OVA_A]/\`+@8&
M_*9]/?PC\G;EYL*>B7&E.1)VIT$]SZ[8L$'4\8&Y4&G[P*^9-!"XI1Y2A[)A
M6;+E]0%00'I@11+?]%5R\CI]\TIG)G4%EKJ2B@1\S*Q,S7GSI(%!!,R\25>3
M!NN$2J@"A$G#V=
M@F[4XH`(@8Y3E`WV#@2Z/%-X9.*7B:JMK3T:>SVW8VR648TV'LVXR"+N2FVL
M6<%FT9"L&R*3:"@?F2@O\L!UQ%;\0J#\`"TZS?3#^-JW[U8-U*6*W523K[>2;1\Q39E6%DTTY,J(*E!P
M0JA>@"B'Q*/QP+:)WQZ1$Y3:34S;QV\Q_1A))L9VPL*R*-G:R)T3F):F@&,,
MHNA[/X%/<)TZCZ8';(+@I5H;7[JBN-K;Q/L]QOCU]`_)/@%7FK"&;1VU]D-'K`2+2WU#F9X$L)>L5^K#N[;23>%D[9)&E!GE59M5\>K>4CVS1+D-N^#5;%20.M7K0
MK&)OD$.H$7D4.B_S4FJ4P^\OW%]P>@]H=,#WJ;P#1IMUH-N3WYN&Q(T:=;3I
M86U3ZLNUFSMBJ%39RIA,A[[5'W1]HO;^#J/QZX&0P/L]/@'3K_%T^'[!P/+`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8'Y*$353.DLD15)0IB*)*$*H10A@$IR'(8.TQ3`
M/J`@("&!$"\O?TINC.7^XY662;MB
ME/1IF5DUSKNWB97**ISB/LEP(C*O"WZ@3Q*6&1>:ZJG)_5,0W=J*.;AI63EK
M+K>:,Q]PBP?,QA7$>\0,@41$JKZI+,:S+;+V)^:^T4
M4$IS5#Q>8>D5Z&(H<19)F<#T'T$"^@8'MJ_4,>>Q!%5RM?[RF@GU!14^G9`J
M:?8H"1NIA9="]%!Z#^W`\(KZASST3L@2(A]B721DU/YK%IJ%XJZ'\`J=?:*T
M[B@)`Z^O3J&!W'_KM_4/?U[LO_DN_P#^$P'_`%V_J'OZ]V7_`,EG_P#PF`_Z
M[?U#W]>[+_Y+/_\`A,#Q4\[OU#@$.8T]LLA0*<3[\.TO:/4P#\IZ=H>N!
M,+V[L3D3R9^FFV1?=UQEBLO('8''=RXL\8E6EHVP2,S^LV*2:1*Z1159)8&J
M11[0$1$H=V!%>^E?I6VN/O-+D)M^ZZEOL3#Z]X>[8NX'FZW*Q#1^XK#5*PLH
MPKIXV2+[TFI%"DF!0,81Z^F!(?\`'CPEXQ-#WS4>3"5FN1>V+F>];[8!:
MK-*.J%QVUEJRQSLY4Z/0*HQN)BX[C"91T3L$`Z#U"M$;YQN;$?0
M*5SNOWCU2K'BZO=M@X%OM)OL_P#,-[U'7UFM[.JUK>]JU:%:03:TB<5D6JJ:
M!7@G*@X(<3_#J%,;S]0=RV79#R$T3PAJ6T.%^U.04CQ#XV7J5V^6JWZU[F;S
MR]:CKK:ZP-8E"PNM9.5;FZ*@J8Q4A*/=UZC@57:>>+D#4%;CQ$V?P_C77E1B
MMX5G0U$X^T78(S.J;_(VVA-MEL]BGV::"0&!I<)3EE7+TYF2Q@,W$H=.[\(?
M:L7GL^7U:IM7N''FBZ:NAMBT3E>E?+W$ZTK47K^SK0L,
MM%R[&\V!LSD$5&ZHH-TU5Q_F"00[U7/+MS"XP;"I%9\K?#JL<=:+NVE[,NFH
M=DZ=V8;;+%E-:TU]/;3FM47^,&OP1H.YA3JXZ.B)5E"+.2`G\1ZE"V+8WFHY
M12FF$9WE1PCG../&'F]I/>R'%/<5)W."^STI2/T]=KW0TKS%%K")M;3FP:O#
ME?4&72%UMI3CUQ1::'5G=%<>]863?%XYRI/:_"(B%;&?U-]VW[<-*:RXA<
M8M?C>-A:VE[=9W_*'WP%NOK_'@?FE
M5ZR@J*Z%=@D5A#H*R41'IJB`!T`!4(W`X@`?MP/;_)HC^JHW_<6O^JP'Y-#_
M`-51O^XM?]5@/R:'_JJ-_P!Q:_ZK`?DT/_54;_N+7_58'N?+-_9^6^70^7[>
MWV/:3]GM^/;[7;V=O7[.F!\MY78%_'R,6[AXU>/EV#N+DVAF:`(/HY\@HV>,
MG12$+[C9RW4,0Y1]!`V!&7DO$QY%.+\?MSC1P8Y#:?M7CWY'3MU"U:&Y"U5[
M)6?0]8VX[>M]FQ.GK:PD2)*1SMG/OWC)LJT*"#T4S=1$#&.'38_Q(>4^PZ.H
M_C)V/RDTNY\YE`4,
M=5FE_,```,#ME;\(^^*IPCX]<68&YT!@ZTIY*9SE@BH#ATM&$TT?93_A9S.U/YW>._(KCGL;6,!LGEIOU&9T
M&M:V:TG$P#K5_'9]!VJ)O['L(48RQL(MP@B8##^)<.G40[<#(OL;PC\O>?ED
MV5R7\A>]]CI2`=*:\X]OZ#L."VRTM,ND^>(KW)_9;="?+/2
M']GL8+J@`B/:&!USD9XR/,_SODM2RG+;?7&-K#:7B-T14%1-8UF0B(RT6;9.
MBKIK%KLN;DW"CPZ+G\QLA2A%D3!)JW.H8JAA_"(5OYY>(+DURF\??C^XPU2\
MZXB]E\5(4D?=IF:%T:NR[EMQ\L6IVCB$]ML*@^S.2:+@.XI>B11_BP+9-?\`
M@NY;\.$(JS<48[AKN"4VEKNE1N^];`P&!QZ=
M/LZ?R?'_`+\#G`8#`8#`X'IT]?AU#_"&`#I_*/Q^/7_)_)@/3K]O_9UZ^G_A
M8`>GV_?_``_D_DP*$;*_L[?O/TI^]3]W7[VOSZ8_<-^J?R[]7?J+\E>?G?Z#
M^:_VS\P_(??]_P!CU]CNZ^F!7C`X].O]T>G][UZ8'.`#^[\1^/\`'@!Z?;_+
5_#[L#Q].O\/AT_\`%_[<#RP&!__9
`
end
-----END PRIVACY-ENHANCED MESSAGE-----